Research Article

Different Genotype Distribution of Human Papillomavirus between Cervical and Esophageal Cancers: A Study in Both High-Incidence Areas, Xinjiang, China

Yi Zheng,1 Yage Fan,2 Yan Zeng,3 Shiyu Liu,2 and Limin Gao4

1Department of Gastroenterology, First Affiliated Hospital, School of Medicine, Shihezi University, Xinjiang, China
2Shihezi University School of Medicine, Xinjiang, China
3Key Laboratory of Xinjiang Endemic and Ethnic Disease & Department of Biochemistry, School of Medicine, Shihezi University, Xinjiang, China
4Department of Gynecology and Obstetrics, First Affiliated Hospital, School of Medicine, Shihezi University, Xinjiang, China

Correspondence should be addressed to Limin Gao; daisyglm@163.com

Received 20 August 2020; Revised 7 November 2020; Accepted 27 November 2020; Published 7 December 2020

Academic Editor: Maciej Gagat

Copyright © 2020 Yi Zheng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The aim of this study is to reveal the certain human papillomavirus (HPV) genotype distribution between cervical cancer and esophageal cancer in the both high-incidence geographic regions. For this study, we collected and detected the infection of HPV in 120 paraffin-embedded esophageal tissues and 152 paraffin-embedded cervical tissues, respectively. The esophageal tissues include 40 normal epithelium (ENOR), 26 dysplasia (DYS), and 54 invasive squamous cell carcinoma (ESCC). The cervical tissues consisted of 40 normal epithelium (CNOR), 53 intraepithelial neoplasia (CIN), and 59 invasive squamous cell carcinoma (CSCC). Both esophageal and cervical tissues collected in this study came from the same area, in which both the ESCC and CSCC were in high incidence, Xinjiang province, China. HPV GenoArray test kits were served to analyze the HPV infection. The result shows that among the 59 CSCC tissues, the total infection rate of HPV was 98.3% (58/59). The positive rate of HPV-16 infection was 63.8% (37/58). It indicated that HPV-16 is the most common infection among all of the high-risk HPV. The multiple infection rate was 19.0% (11/58). Among the 54 ESCC, a total of 7 genotypes were detected. The total infection rate of HPV was 61.1% (33/54). The positive rate of HPV-16 infection was 63.6% (21/33). The multiple infection rate was 6.1% (2/33).

Our result shows that high-risk-type HPV-16 was associated with both cervical cancer and esophageal cancer, which play a role in the high-incidence area in Xinjiang. We hope that our results could point out the direction for the treatment strategy of HPV-associated cancer, cervical cancer, and esophageal cancer and for the application of HPV vaccines in the future.

1. Introduction

Human papillomavirus (HPV) is an extremely common pathogen for human infection and can cause many benign and malignant diseases, including cervical, anal, vulvar, penile, and oropharyngeal cancers [1]. Meanwhile, its genotyping is closely related to pathogenicity. There are more than 100 subtypes of HPV, which are divided into high risk and low risk based on their propensity to cause cancer. It was reported that high-risk human papillomaviruses (HR-HPVs) brought about more than 600,000 cancers in 2008, which bring huge pressure and enormous challenges for public health [2]. Infection by high-risk anogenital HPV is a necessary cause of cervical cancer (CC) [3]. HR-HPV-associated cancers closely correlated with different anatomic sites, geographical areas, and smoking status, leading to almost 100% cervical cancer, 88% anal cancer, and less than 50% lower genital tract and oropharyngeal cancer [4].

However, due to healthcare disparities, unbalanced economic development, and unhealthy lifestyle, the developing countries have a higher incidence and mortality rates of cervical cancer. According to global cancer statistics in 2018, the number of new cases and deaths of the cancer reached 315,346 and 168,411, respectively, in Asia. In addition, the
incidence and mortality rates were 3 to 5 times higher than Northern American and Australia/New Zealand [5]. In 2018, it was evaluated that there were 106,430 new cases and 47,739 deaths all over the country [6]; cervical cancer is regarded as one of the top six cancers among women in China, especially in parts of rural area [7]. For example, in the southern part of Xinjiang, the morbidity (up to 590/100,000) and mortality rate of cervical cancer is the highest in the whole country [8]. It is worth nothing that the incident and death rates of esophageal cancer are also high in these regions.

Esophageal cancer is the ninth most common malignancy around the world; multiple factors including drinking, smoking, eating habits, poverty, and history of head and neck cancer are involved in its complex and multistage mechanism [9]. What is more, studies in the past 20 years have shown that the HPV plays a crucial role in the development and progression of esophageal cancer as a cofactor or oncogene. But its idiographic action mechanism is to be addressed. In China, infectious agents contributed more than one-quarter of the overall cancer cases [10]. The infection agents have been recognized as either direct carcinogens or promoters in esophageal carcinogenesis. HPV has been suggested as distinct possible cause of esophageal carcinogenesis [11].

The study of HPV genotyping in invasive cervical cancer shows that the distribution and prevalence of HPV vary by geographic region and race [12]. Located in the northwest of China, Xinjiang has long been inhabiting 47 ethnic groups such as Han, Uygur, and Kazak. Because of a large population and complex landforms, both cervical cancer and esophageal cancer were in high incidence in this area. It has been reported that the incidence of cervical cancer ranges from 459/100,000 to 572/100,000, which is significantly higher than the national incidence (14.6/100,000) [13]. Esophageal cancer also has a high incidence in Xinjiang, up to 150/100,000. However, the certain difference of HPV genotype distribution between these two cancers in the same geographic regions is not clear. In this study, we used PCR and Gene Chip to detect and genotype the HPV, respectively, among paraffin-embedded esophageal and cervical tissues to find the difference of HPV infection between cervical cancer and esophageal cancer, hoping that our results could point out the direction for targeted therapy of HPV-associated cancer, cervical cancer, and esophageal cancer and for the application of HPV vaccines.

2. Materials and Methods

2.1. Study Subjects

2.1.1. Source of Cervical Samples. All of the paraffin-embedded cervical samples were from the First Affiliated Hospital of Shihezi University, Xinjiang, China; healthy control and patients with cervical precancerous lesions were selected randomly from who underwent colposcopy examination, and patients with CSCC received surgical treatment. All cases were confirmed by histological examination of tissue from biopsy or resected specimens during 2010-2018. The study group included a total of 152 subjects and being composed of a control group of 40 normal cervical epithelium (CNOR), two study groups of 53 cases and 59 cases diagnosed with intraepithelial neoplasia (CIN), and 59 invasive squamous cell carcinoma (CSCC), respectively.

2.1.2. Source of Esophageal Cancer Tissues. All of the tissues were paraffin-embedded esophageal tissues which were collected from the First Affiliated Hospital of Shihezi University, Xinjiang; Friendship Hospital of Yili, Xinjiang; Xinjiang Production and Construction Corps Agriculture 4th Division Hospital; and People’s Hospital of Yili, Xinjiang, during 2010-2018. A total of 120 cases of esophageal tissues are from the Kazak people of Xinjiang. All of the cases were observed under an optical microscope, including 40 normal epithelium (ENOR), 26 dysplasia (DYS), and 54 invasive squamous cell carcinoma (ESCC). Healthy subjects and patients with esophageal precancerous lesions were confirmed by early esophageal cancer screening. Esophageal biopsy tissues were divided into normal and DYS depending on cellular morphological changes and tissue architecture. The ESCC tissues came from the patients who underwent the surgical treatment.

2.2. Methods

2.2.1. Sample Collection. Biopsy materials and surgical specimens were collected and processed by standardized methods to minimize the possibility of HPV contamination in the environment. Both the esophageal and cervical tissues were fixed with formalin and embedded in paraffin.

2.2.2. Histopathological Examination. The cervical intraepithelial neoplasia terminology was used for classification of cervix biopsy tissues. The histopathological examinations and TNM staging of cervical cancer specimens and esophageal cancer specimens were performed according to the TNM classification given by the UICC criteria of 2002 [14] and FIGO criteria of 2009 [15], respectively.

2.2.3. DNA Extraction. The DNA extraction procedures in the paraffin-embedded both esophageal and cervical tissues are as follows: 10 pieces of 5 μm paraffin-embedded tissues were treated with xylene for dewaxing. Then, it was added with 30 μl proteinase K (20 mg/ml) and incubated overnight under 55°C. Then, DNA was extracted by the same method with cervical cells (reagents, purchased from Sangon Biotech (Shanghai) Co. Ltd).

2.2.4. PCR. The relevant segment of the HPV L1 gene was amplified by general consensus primers GP5+/GP6+ (GP5 +5'TTTGT TACTG TGGTA GATAC TAC-3', GP6+5'-GAAGAGCCAAG-GACAGGTAC-3') [16]. The 268bp fragment of the β-globin gene was amplified by Glob-F (5'-CAACCTTCAT-CACGTTGCC-3') and Glob-R primer (5'-GAAGAGCCAAG-GACAGGTAC-3') to confirm the existence of human genomic DNA. Each group of PCR had negative control which was a reaction solution without template DNA. For reaction system and conditions, refer to reference [17]. Positive PCR products were used for HPV genotyping (reagents purchased from Tiangen Biotech (Beijing) Co. Ltd).
2.2.5. HPV Genotyping. HPV genotypes were analyzed by commercial HPV GenoArray kit (Yaneng Bioscience (Shenzhen) Co. Ltd.) for detection and genotyping of 23 HPV types (HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-73, HPV-82, HPV-6, HPV-11, HPV-42, HPV-43, HPV-82, HPV-53, HPV-66, HPV-83), including all the 13 high-risk HPV genotypes. All the operations were conducted in strict accordance with the manufacturer’s agreement. The identification of the results was also based on the manufacturer’s instructions. 23 HPV subtypes can be identified by HPV genotyping. All HPV subtypes were represented by Arabic numerals. The different concentrations of DNA were the reason for the different intensity of positive “blue spot.” When the DNA concentration of the sample was high, there was a “blue dot” in the internal control (IC).

3. Results

Total samples were tested using the HPV GenoArray kit; 165 (60.7%) cases were positive. Among the positive samples, 37 cases of cervical and 21 cases of esophageal cancers were HPV-16 subtypes.

3.1. Genotypes Detected in Cervical Tissues. Of the 152 samples analyzed, 73% (111) were HPV-positive by Gene Chip. 20 of the 23 HPV genotypes, which the Gene Chip contains, were detected. The increasing risk of CIN and CSCC, respectively (CIN vs. CNOR: OR = 43.94, 95%CI = 9.44 -204.56; CSCC vs. CNOR: OR = 105.56, 95%CI = 21.54 -517.19) was observed. There was infection with high-risk HPV types of CIN and CSCC by 43.94-fold and 105.56-fold. There was a significant correlation between infection with high-risk HPV types and the progression of CSCC (P < 0.001) (Table 1).

3.2. Genotypes Detected in Esophageal Tissues. The detection rate of high-risk types was 76% (41/54) of 120 samples. Infection with high-risk HPV types increased the risk of DYS by 6.53-fold (DYS vs. ENOR: OR = 6.53, 95%CI = 1.57 -27.21) and ESCC by 14.31-fold (ESCC vs. ENOR: OR = 14.31, 95%CI = 3.93 -52.10).

3.3. Distribution of HPV Subtypes in 152 Cervical Samples. HPV-DNA testing including all of the 23 different HPV types was performed in a total of 152 cervical tissues. The 111 HPV-positive samples were detected (CNOR: 9, CIN: 44, CSCC: 58). The high-risk HPV genotypes account for 80.2% (89/111) of the total positive rate of cervical samples. HPV-16 was identified in a total of 64 among the 152 positive cases, which was the most frequent viral type. HPV-11 was the most frequent low-risk type; it accounts for 66.7% (10/15) of the total low-risk types (Table 2). Single-type infections were identified in 47 cases, accounting for 81%. Double infection was predominated among the multiple infections, accounting for 45.5%. The more the types of samples infected, the lower the cases detected (Table 3). Among the double infections, HPV-16 combined with other types was dominant. HPV-16 combined with HPV-33 was the most frequent form.

3.4. Distribution of HPV Subtypes in 120 Esophageal Tissues. Of the 120 samples analyzed, 45% (54) were HPV-positive by Gene Chip. Seven of the 23 HPV genotypes, which the Gene Chip contains, were detected. The 54 HPV-positive samples detected were as follows: ENOR: 8, DYS:13, and ESCC:33. HPV-16 was identified in a total of 30 among the 54 positive cases, which was the most frequent viral type. Four high-risk HPV genotypes were detected, with the sequence as HPV-16 (30), HPV-18 (7), HPV-59 (1), and HPV-45 (1). And the most frequent low-risk genotypes were detected (Table 2). Among the 54 positive samples, single infection accounts for 93.9% (31). Multiple infections were identified in 2 cases. All of the multiple infections are double infection.

3.5. Clinical Pathological Characteristics. The prevalence of high-risk HPV types in CSCC patients (84.7%) was higher than that in ESCC patients (53.7%). There was no significant difference between esophagus and cervix than in precancerous tissue.

And then, we try to analyze whether the clinical pathological characteristics were associated with both CSCC and ESCC with HPV infection. However, there was no significant difference in age between over the age of fifty (75.0) and under the age of fifty (87.2) HPV infection CSCC patients (P = 0.547). Similarly, there was no significant difference in ESCC (P = 0.625). Among the 59 CSCC samples, 13 cases were positive with HPV infection; 19 cases were positive for lymph node metastasis; the rate of HPV infection was 68.4%, but in negative lymph node metastasis, the HPV infection rate was 92.5%. However, the difference was statistically significant among lymph node metastasis (P = 0.044). In this study, there are no statistically significant correlations found between positive HPV infection and the age or gender of patients, tumor stage, tumor cell differentiation, or lymph node metastasis in ESCC (P > 0.05).

Also, there is no significant association found between infection with high-risk HPV types and gender, age, lymph node metastasis, clinical stage, or differentiation in both CSCC and ESCC patients (Table 4).

4. Discussion

At present, over 100 HPV genotypes have been isolated, of which 13 of them have been found to be associated with malignant tumors, including cervical cancer and esophageal cancer, and therefore were classified as high-risk types. Both of cervical cancer and esophageal cancer are in high
incidence in Xinjiang. However, the certain difference of HPV genotype distribution between these two cancers in the same geographic regions is not clear. In this study, we used PCR and Gene Chip to detect and genotype the HPV, respectively, among para-n-embedded esophageal and cervical carcinoma tissues to find the difference of HPV infection between cervical cancer and esophageal cancer, in order to provide useful reference data for the prevention and treatment of HPV-associated cancer, cervical cancer, and esophageal cancer. HPV vaccine has been applied in numerous western countries for many years, but it was approved in China in 2018. The current design and validation of vaccines are based primarily on the epidemiological background of western populations, lacking of data of the certain HPV genotype distribution in Asia; thus, the protection rate in Asian populations is relatively lower than that in western populations. This study also can provide useful data for the application of HPV vaccines in the future in Xinjiang China.

Table 1: HPV prevalence in different cervical and esophageal lesions.

| Diagnosis | N  | n (%) | High risk | n (%) | OR       | 95% CI    | n (%) | Low risk | n (%) | P   |
|-----------|----|-------|-----------|-------|----------|-----------|-------|----------|-------|-----|
| Cervical  |    |       |           |       |          |           |       |          |       |     |
| CNOR      | 40 | 2     | 5         |       | <0.001   | 43.94     | 9.44-204.56 | 7    | 17.5    |     |
| CIN       | 53 | 37    | 69.8      |       | <0.001   | 105.56    | 21.54-517.19 | 7    | 13.2    | 0.57 |
| CSCC      | 59 | 50    | 84.7      |       | <0.001   | 14.31     | 3.93-52.10  | 8    | 13.5    | 0.59 |
| Esophageal|    |       |           |       |          |           |       |          |       |     |
| ENOR      | 40 | 3     | 7.5       |       |          | 1         | 44.4 |          | 5     | 12.5  |
| DYS       | 26 | 9     | 34.6      |       | 0.005    | 6.53      | 1.57-27.21 | 4    | 15.3    | 0.74 |
| ESCC      | 54 | 29    | 53.7      |       | <0.001   | 13.9      | 7.4   |          | 0     |     |

Table 2: Distribution of HPV genotype in HPV-positive cases.

| Diagnosis | HPV-16 | HPV18 | HPV56 | HPV59 | HPV33 | HPV45 | HPV6 | Low risk | HPV11 | HPV43 |
|-----------|--------|-------|-------|-------|-------|-------|------|----------|-------|-------|
| Cervical  | 50     | 3     | 69.8  |       | 0.005 | 6.53  | 15.3 | 0.74     | 12.5  | 0     |
| CIN       | 44     | 26    | (59.1)| 5     | 1 (1.1)| 0     | 0    | 0        | 0     | 0     |
| CSCC      | 58     | 37    | 63.7  |       | 5     | 8.6   | 3.93 | 1 (1.7)  | 0     | 0     |
| ESophageal| 40     | 3     | 7.5   |       | 0     | 0     | 0    | 0        | 0     | 0     |
| ENOR      | 8      | 3     | 37.5  |       | 0     | 0     | 0    | 0        | 0     | 0     |
| DYS       | 13     | 6     | 46.2  |       | 2     | 3.2   | 0    | 0        | 0     | 0     |
| ESCC      | 33     | 21    | 63.6  |       | 5     | 15.2  | 0    | 0        | 0     | 0     |

Table 3: HPV-positive rates of infection types in CSCC and ESCC patients.

| HPV-positive rates (%) | Single-type infection (%) | Co-infection | Multiple-type infection (%) | Tri-infection | Quainfection | Seven infections |
|------------------------|---------------------------|--------------|-----------------------------|---------------|--------------|------------------|
| CSCC (n = 59)          | 98.3 (58/59)              | 81.0 (47/58) | 45.5 (5/11)                 | 18.2 (2/11)   | 18.2 (2/11)  | 18.2 (2/11)      |
| ESCC (n = 54)          | 59.3 (33/54)              | 93.9 (31/33) | 100 (2/2)                   | 0             | 0            | 0                |

We detected 152 paraffin-embedded cervical tissues (CNOR40, CIN53, CSCC59) and 120 esophageal tissues (ENOR40, DYS26, ESCC54). A total of 272 samples were enrolled to detect and genotype HPV DNA by PCR and Gene Chip. The positive cases were diagnosed as cervical normal epithelia (n = 9) or cervical intraepithelial neoplasia (n = 44) or cervical carcinoma (n = 58) or esophageal normal epithelia (n = 8) or esophageal dysplasia (n = 13) or esophageal carcinoma (n = 33). Overall, positive cases that were infected with high-risk genotype were comparatively low in normal tissues from the cervix (5%) and esophagus (7.5%) but have a relatively higher rate in precancerous lesions and cancerous tissues, which were, respectively, CIN: 69.8%, CSCC: 84.7%, DYS: 34.6%, and ESCC: 53.7%. Our result shows that with infection of high-risk type, it was increased fortyfold and hundredfold to CIN and CSCC; it also increased thirtyfold and fiftyfold to DYS and ESCC. The infection rate of HPV and the mortality and morbidity of cervical cancer have been rising every year; age of onset has a younger trend (25- to 45-
year-old) [18], which has seriously threatened women’s health and lives. Early screening provides a crucial method for early detection, effective treatment, and reducing mortality. However, the rate of cervical cancer screening in China is lower than the target set by the WHO Global Monitoring Framework. According to the report [18], in 2010, only one-fifth of the women in China had been screened, and the screening rate in Xinjiang was estimated to be lower, related to the vast territory, complex population composition, language communication barriers, and fewer study sites (there are only one urban study site and five rural study sites in Xinjiang). We hope that in the future work, screening services would cover the high-risk population in Xinjiang, pay more attention on strengthening health care knowledge publicity and education, and improve the screening participation in rural areas, so as to reduce the infection rate of HPV and the incidence of cervical cancer.

Our results indicated that HPV-16, HPV-18, and HPV-56 were the most current viral type among cervical cancer in Xinjiang. A global study shows that HPV-16, HPV-31, and HPV-18 were the main types among the women with normal thinprep cytologic test (TCT) diagnosed in Europe; HPV-16, HPV-18, and HPV-33 in Asia; and HPV-16, HPV-58, and HPV-18 in South America [19]. A number of epidemiological studies have shown that high-risk HPV is the principal cause of invasive CSCC and CIN; seventy percent of these have close relationship with HPV-16 or HPV-18 [20]. Previous studies also reported the five most prevalent HR-HPV genotypes in cervical cancer in Yunnan Province, Southwest China, were HPV-16 (3.4%), HPV-56 (1.7%), HPV-58 (1.4%), HPV-33 (1.2%), and HPV-52 (0.88%) [21]. Data from ICO/IARC HPV Information Centre shows that the five most common HR-HPV genotypes in cervical cancer in China were HPV-16 (59.5%), HPV-18 (9.6%), HPV-58

| Variables                        | Cases (n.) | HPV infection | χ²  | P    |
|----------------------------------|------------|---------------|-----|------|
|                                   |            | Positive (%)  | Negative (%) |     |
| CSCC patients                     |            |               |               |     |
| Age (years) <50                   | 12         | 9 (75.0)      | 3 (25.0)      | 0.363 | 0.547 |
| age ≥50                           | 47         | 41 (87.2)     | 6 (12.8)      |     |
| Clinical stage I                  | 38         | 33 (86.8)     | 5 (13.2)      | 0.050 | 0.823 |
| Clinical stage II                 | 21         | 17 (81)       | 4 (19)        |     |
| Differentiation High              | 32         | 27 (84.4)     | 5 (15.6)      |     |
| Differentiation Middle            | 12         | 8 (66.7)      | 4 (33.3)      | 5.508 | 0.039 |
| Differentiation Low               | 15         | 15 (100)      | 0 (0)         |     |
| Lymph node metastasis Positive    | 19         | 13 (68.4)     | 6 (31.6)      | 4.065 | 0.044 |
| Lymph node metastasis Negative    | 40         | 37 (92.5)     | 3 (7.5)       |     |
| ESCC patients                     |            |               |               |     |
| Age (years) <50                   | 24         | 12 (50.0)     | 12 (50.0)     | 0.238 | 0.625 |
| age ≥50                           | 30         | 17 (56.7)     | 13 (43.3)     |     |
| Gender Male                       | 31         | 19 (61.3)     | 12 (38.7)     | 1.685 | 0.194 |
| Gender Female                     | 23         | 10 (43.5)     | 13 (56.5)     |     |
| Tumor stage I                     | 33         | 16 (48)       | 17 (52)       | 0.930 | 0.335 |
| Tumor stage II                    | 21         | 13 (61.9)     | 8 (38.1)      |     |
| Differentiation High              | 17         | 8 (47.1)      | 9 (52.9)      |     |
| Differentiation Middle            | 22         | 11 (50.0)     | 11 (50.0)     | 1.437 | 0.487 |
| Differentiation Low               | 15         | 10 (66.7)     | 5 (33.3)      |     |
| Lymph node metastasis Positive    | 18         | 11 (61)       | 7 (39)        | 0.596 | 0.440 |
| Lymph node metastasis Negative    | 36         | 18 (50)       | 18 (50)       |     |
(8.2), HPV-52 (6.5), and HPV-33 (3.5%) [6]. The survey focused on HPV genotyping has discovered that HPV-16 and HPV-58 are the most common types of cervical cancer in 14 provinces of China. Our results show that among the total of 58 CSCC with HPV infection, the two of these cases account for a large proportion. But the most prevalent HPV genotypes in these 54 positive results of ESCC were HPV-16 and HPV-18. In the past 20 years, the reported HPV infection rates of CSCC patients have always been higher than those of ESCC patients form different regions [22, 23]. In our study, we also come to the conclusion of the sample that the HPV infection rate was higher in CSCC than in ESCC (HPV-positive rates: CSCC: 98.3%, ESCC: 59.3%). However, the HPV infection rates in normal epithelium or precancerous lesions did not differ significantly between esophagus and cervix. Our data confirmed that HPV-16 and HPV-18 are the most frequent viral type in both esophagus and cervix. The high-risk HPV types have strongly suggested a possible role of oncogenic HPV infection in carcinogenesis of CSCC and ESCC in Xinjiang [24]. For now and in the time to come, we appeal for more research that could devote to take large-scale investigation in order to explore the distribution of different HPV genotypes in different regions [25] and focus our efforts on improving the popularization rate of early screening and the propaganda of prevention knowledge.

In conclusion, our data show that HPV infection plays an essential role in both cervical and esophageal carcinogenes. The high-risk types may be positively promoting the occurrence and development in ESCC. High-risk-type HPV-16 was associated with both cervical cancer and esophageal cancer, which play a role in the high-incidence area in Xinjiang. Further studies are needed to elucidate the role of HPV between esophagus carcinogenesis and cervical cancers and study design and analyze the national and regional differences, providing a more accurate assessment of type-specific HPV risk on these cancers.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Acknowledgments

The authors acknowledge all of the investigators and staff who took part in this study at the Key Laboratory of Xinjiang Endemic and Ethnic Disease & Department of Biochemistry, School of Medicine, Shihezi University.

References

[1] J. Betiol, L. L. Villa, and L. Sicbero, “Impact of HPV infection on the development of head and neck cancer,” Brazilian Journal of Medical and Biological Research, vol. 46, no. 3, pp. 217–226, 2013.

[2] C. De Martel, M. Plummer, J. Vignat, and S. Franceschi, “Worldwide burden of cancer attributable to HPV by site, country and HPV type,” International Journal of Cancer, vol. 141, no. 4, pp. 664–670, 2017.

[3] M. Jacot-Guillarmod, J. Pasquier, G. Greub, M. Bongiovanni, C. Achtari, and R. Sahli, “Impact of HPV vaccination with Gardasil® in Switzerland, BMC Infectious Diseases, vol. 17, no. 1. p. 790, 2017.

[4] A. R. Giuliano, A. G. Nyitray, A. R. Kreimer et al., “EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection,” International Journal of Cancer, vol. 136, no. 12, pp. 2752–2760, 2015.

[5] F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. Torre, and A. Jemal, “Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a Cancer Journal for Clinicians, vol. 68, no. 6, pp. 394–424, 2018.

[6] ICO/IARC Information Centre (ES), Human papillomavirus and related cancers, fact sheet 2018: China, ICO/IARC HPV Information Centre, Barcelona, 2019, https://www.hpvcentre.net/statistics/reports/CHN FS.pdf?t=1576463840367.

[7] J. F. Shi, K. Canfell, J. B. Lew, and Y. L. Qiao, “The burden of cervical cancer in China: synthesis of the evidence,” International Journal of Cancer, vol. 130, no. 3, pp. 641–652, 2012.

[8] A. Abudukadeer, S. Azam, A. Mutailipu, Q. Liu, G. L. Guo, and S. Mijitti, “Knowledge and attitude of Uyghur women in Xinjiang province of China related to the prevention and early detection of cervical cancer,” World Journal of Surgical Oncology, vol. 13, no. 1, pp. 110–117, 2015.

[9] F. Kamangar, W. H. Chow, C. A. Christian, and M. D. Sanford, “Environmental causes of esophageal cancer,” Gastroenterology Clinics of North America, vol. 38, no. 1, pp. 27–57, 2009.

[10] W. Xiang, J. F. Shi, P. Li et al., “Estimation of cancer cases and deaths attributable to infection in China,” Cancer Causes & Control, vol. 22, no. 8, pp. 1153–1161, 2011.

[11] S. K. Zhang, L. W. Guo, Q. Chen et al., “The association between human papillomavirus 16 and esophageal cancer in Chinese population: a meta-analyses,” BMC Cancer, vol. 15, no. 1, pp. 1096–1117, 2015.

[12] W. Gú, S. Sun, A. Kahn et al., “Cervical cancer cell lines are sensitive to sub-erythral UV exposure,” Gene, vol. 688, no. 1, pp. 44–53, 2019.

[13] S. Z. K. Lalai, A. E. Noffssinger, C. M. Maimaitiaili, and P. Fenoglio, “Detection of human papillomavirus DNA in cervical squamous cell carcinoma in Xinjiang Uyghur women,” Chinese Journal of Obstetrics and Gynecology, vol. 32, no. 7, pp. 405–408, 1997.

[14] D. R. Byrd, M. A. Carducci, C. C. Compton, A. G. Fritz, and F. L. Greene, AJCC Cancer Staging Manual, Springer-Verlag, New York, 2002.

[15] Figo Committee on Gynecologic Oncology, “Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia,” International Journal of Gynecology and Obstetrics, vol. 105, no. 1, pp. 3–4, 2009.

[16] M. Liu, X. Yan, M. Zhang, X. Li, S. Li, and M. Jing, “Influence of human papillomavirus infection on the natural history of cervical intraepithelial neoplasia 1: a meta-analysis,” BioMed Research International, vol. 2017, 9 pages, 2017.
[17] G. Abulizi, H. Li, P. Mijiti et al., "Risk factors for human papillomavirus infection prevalent among Uyghur women from Xinjiang, China," *Oncotarget*, vol. 8, no. 58, pp. 97955–97964, 2017.

[18] B. Wang, M. He, A. Chao et al., "Cervical cancer screening among adult women in China, 2010," *The Oncologist*, vol. 20, no. 6, pp. 627–634, 2015.

[19] G. M. Clifford, S. Gallus, R. Herrero et al., "Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis," *The Lancet*, vol. 366, no. 9490, pp. 991–998, 2005.

[20] WHO, *Comprehensive cervical cancer prevention and control: a healthier future for girls and women*, 2013, http://www.who.int/reproductivehealth/topics/cancers/en/.

[21] L. L. Sun, Q. Jin, H. Li et al., "Population-based study on the prevalence of and risk factors for human papillomavirus infection in Qujing of Yunnan province Southwest China," *Virology journal*, vol. 9, no. 1, pp. 153–161, 2012.

[22] K. J. Syrjanen, "HPV infections and oesophageal cancer," *Journal of Clinical Pathology*, vol. 55, no. 10, pp. 721–728, 2002.

[23] A. Hildesheim and S. S. Wang, "Host and viral genetics and risk of cervical cancer: a review," *Virus Research*, vol. 98, no. 2, pp. 229–240, 2002.

[24] H. Faust, A. E. Eldenhed, A. Roslin, J. Wennerberg, and O. Forslund, "Prevalence of human papillomavirus types, viral load and physical status of HPV16 in head and neck squamous cell carcinoma from the South Swedish Health Care Region," *Journal of General Virology*, vol. 97, no. 11, pp. 2949–2956, 2016.

[25] J. Li, J. Mei, X. Wang, L. Hu, Y. Lin, and L. Yang, "Human papillomavirus type-specific prevalence in women with cervical intraepithelial neoplasm in Western China," *Journal of Clinical Microbiology*, vol. 50, no. 3, pp. 1079–1081, 2012.